Pivotal readout

UCB's bimekizumab keeps its edge over risankizumab in psoriatic arthritis at week 24

In BE BOLD, a Phase 3b head-to-head study, 54.9% of patients on Bimzelx reached ACR50 at week 24, compared with 43.8% on Skyrizi, extending the superiority shown at week 16. The top-ranked secondary endpoint missed significance, and complete skin clearance was about equal. Localized Candida infections were more common with Bimzelx, and full results go to ACR Convergence.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of IL-17A and IL-17F messenger proteins docking on IL-17 receptor complexes on a cell surface, and a Y-shaped antibody catching the messengers in the fluid outside the cell so the receptors stay empty and the signal inside the cell fades.
Bimekizumab: catching both IL-17A and IL-17F. Watch the mechanism animation on the bimekizumab page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call